Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. - Wikidata - awgldk - TriplyDB

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.

http://www.wikidata.org/entity/Q34004660

about

European guidance for the diagnosis and management of osteoporosis in postmenopausal women Bone quality and bone strength: benefits of the bone-forming approach.Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study.Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal.Strontium ranelate improves bone microarchitecture in osteoporosis.Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis.Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.In Vitro Effects of Strontium on Proliferation and Osteoinduction of Human Preadipocytes Strontium Ranelate: Long-Term Efficacy against Vertebral, Nonvertebral and Hip Fractures in Patients with Postmenopausal Osteoporosis.Glucocorticoid-induced osteoporosis: treatment update and review.Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis Diabetes and change in bone mineral density at the hip, calcaneus, spine, and radius in older women.Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis.Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis.European guidance for the diagnosis and management of osteoporosis in postmenopausal women.Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective.DXA scanning in clinical practice.Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Valid treatment options for osteoporosis and osteopenia in HIV-infected persons.Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring.Bone quality and osteoporosis therapy.Current, new and future treatments of osteoporosis.How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis.Strontium ranelate: a look back at its use for osteoporosis.The role and efficacy of denosumab in the treatment of osteoporosis: an update.Current and future treatment options in osteoporosis.Current options for the management of postmenopausal osteoporosis.Strontium ranelate: in search for the mechanism of action.Goal-directed treatment of osteoporosis in Europe.A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density.Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis.Use of strontium as a treatment method for osteoporosis.Relationships between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene.Femarelle® and bone mineral density - Scientific substantiation of a health claim related to “Femarelle®” and “induces bone formation and increases bone mineral density reducing the risk for osteoporosis and other bone disorders” pursuant to Artic...Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression.Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy.Clinical manifestations of osteoarthritis in osteoporotic and osteopenic postmenopausal women.

P2860

Q24612411-2FFEEBF8-8162-4C7A-8326-FAC44BDAEB6E Q33781595-2ED93DAA-E238-4240-81BC-1AF45BB26000 Q34015680-B5E79742-FAC5-491A-AC00-1A3792AA723E Q34028520-DD9BEC40-ADEC-4D90-8F50-FCD0DCC24793 Q34099162-A3028E73-D24E-427C-8A80-CA162A52E2DF Q34272094-F3F8CE66-99B2-4199-A651-F9D1FDAF51AB Q34612210-21E3BBE9-CD3D-4B37-855E-1549E8D7A1DF Q34727815-B08CF504-BEF7-444E-9567-EEE6B4B6B40C Q35653722-AB116C14-F9E8-4D0E-AD9E-B99BDE29FD26 Q35882535-2FB6CF33-BBCF-4A24-9178-749726E58053 Q36056938-AD90F96B-0437-4EAF-A3F0-AE97346E7D80 Q36059394-0886CFFA-A5F7-4174-AF7A-63A04FE16F09 Q36153174-479568B9-6FBA-4A26-9365-7DECD54A5B05 Q36718819-47E080A7-D089-436A-BF00-3C0A92C07F3A Q36885771-504B7CAC-F826-48E1-A3F9-C86B41B300F0 Q36971112-7A448278-736F-482F-812F-88B7295C6122 Q36997684-875B4049-72BE-4957-89E1-68E7E5E89E16 Q37037296-00A274C6-1A72-4EA7-9BD3-39CA5E88D0F8 Q37101600-EEDDC7F0-05FC-4406-A234-764F658D15F5 Q37107665-AEE89B20-9EA9-4783-AC53-C0CCF19640BB Q37135281-A33F20E3-A0B2-4058-889B-F4C67F14C0F9 Q37138859-2776AE6D-C274-402B-AE60-40C36489F3A8 Q37176381-566F188A-F5DE-4874-A950-C357573417FB Q37756589-43B118B9-8CCE-4669-9920-A5C07EB0FB9F Q37777053-F75DC4BA-F389-45B3-8C8D-D63CED397BB2 Q37784734-632DD962-2008-4358-AAC3-67861820342B Q37807038-54044441-2DAB-4F55-809B-E6A872B3E6CF Q37826197-85171590-4C2F-4F37-B1BF-D64D8629DE6A Q37843715-B2F0EB56-93B8-4256-8144-87B3B5DAAD80 Q37931985-3B987CF1-BF79-44C2-B2E5-AF9F6135D444 Q38127352-A855376E-3B76-4319-8E00-460A953CAFFA Q38246948-4E32875A-9102-47EC-81AE-AA356849F849 Q39554720-64A8FC30-A6BC-45F7-9748-0A061898F616 Q40703352-67F39FC5-2BC0-4C3F-A88C-19301610B08D Q45091227-92CA04B0-527F-4CA3-B588-A80E860BC36E Q46718995-F570C001-62A9-4B20-A239-4A76FB91B408 Q47145658-23F8F160-4348-4F2D-AE78-EBBABFDC5F36 Q53076433-5F500352-B077-4B86-89C4-0C7AB4D78E33 Q54627328-A30BD101-1CBD-4DCE-BE21-EFAE64D75D71 Q55421166-D133C186-DABE-493C-898A-CF3B41E8C670

P2860

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.

http://www.wikidata.org/entity/Q34004660

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Relationship between bone mine ...... eated with strontium ranelate.

@ast

Relationship between bone mine ...... eated with strontium ranelate.

@en

Relationship between bone mine ...... eated with strontium ranelate.

@nl

type

label

Relationship between bone mine ...... eated with strontium ranelate.

@ast

Relationship between bone mine ...... eated with strontium ranelate.

@en

Relationship between bone mine ...... eated with strontium ranelate.

@nl

prefLabel

Relationship between bone mine ...... eated with strontium ranelate.

@ast

Relationship between bone mine ...... eated with strontium ranelate.

@en

Relationship between bone mine ...... eated with strontium ranelate.

@nl

P1433

Q34004660-67350702-00DC-4E08-A233-42570D191865

P1476

Q34004660-D43F2280-5DD1-4186-91FC-A139C1DDBC79

P2093

Q34004660-224F529F-A78A-4ABA-9201-D5DF643F4FEF

Q34004660-59FDCF4E-005B-470F-83CD-F5297EF7DFC6

Q34004660-6184B74B-8397-43C0-9C41-E0C05B46B945

Q34004660-6CBC6112-8342-473D-BC8A-914C4CC21DFE

Q34004660-86DEEFFD-CD4B-4D3D-8DDA-F954C07ED8E8

Q34004660-996FFDAF-5ED8-44E8-A19A-2F1FCE21CEB7

Q34004660-CA84C77E-7EBF-4CCE-975C-3DC4A36D7AE0

Q34004660-D0D48921-DE4B-4515-BDD3-4D52E6315D47

Q34004660-D0E0D643-897A-4202-A584-B47C0E6EF2C0

Q34004660-E6E64AA6-3010-47B2-A5D1-4DFAC4C7D808

P304

Q34004660-63E0FB19-C6E2-4EA6-BFF4-87C6E578F88D

P31

Q34004660-F424AF9B-C5CA-44E6-8EC7-DD863A7DBE3A

P356

Q34004660-EF6EF06D-36DB-4CB2-901C-10990DC31397

P407

Q34004660-023BC188-101E-45DE-8442-AF518E542792

P433

Q34004660-1A71E5D9-8A74-4CDB-A84A-73E24145D4A9

P478

Q34004660-0F9ABC74-1321-4A29-A35E-A445D4A122C2

P50

Q34004660-6EF51F00-3198-467B-BD14-983A3B8FED0E

Q34004660-A65D4B9D-CF5F-4DAE-9E52-42355143A73A

P577

Q34004660-3B3CEEC8-18A1-433A-BD70-8BE667EC8C9C

P5875

Q34004660-6E0FC360-BCFE-44F1-ADE0-E5CAA108E56C

P698

Q34004660-9ED33CC8-2CE4-41F2-ABA3-B712C31487C9

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Relationship between bone mine ...... eated with strontium ranelate.

@en

P2093

Carlina Albanese

http://www.w3.org/2001/XMLSchema#string

Christian Roux

http://www.w3.org/2001/XMLSchema#string

Daniel O Slosman

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Kaufman

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Devogelaer

http://www.w3.org/2001/XMLSchema#string

Johann Detilleux

http://www.w3.org/2001/XMLSchema#string

Manuel Diaz-Curiel

http://www.w3.org/2001/XMLSchema#string

Olivier Bruyere

http://www.w3.org/2001/XMLSchema#string

Patrice Fardellone

http://www.w3.org/2001/XMLSchema#string

Stig Pors-Nielsen

http://www.w3.org/2001/XMLSchema#string

P304

3076-3081

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2006-2758

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Yves Reginster

P577

2007-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6271171

http://www.w3.org/2001/XMLSchema#string

P698

17566094

http://www.w3.org/2001/XMLSchema#string